Diadema Partners’s PureTech Health PRTC Stock Holding History

Diadema Partners’s Portfolio PRTC Stock Details PRTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.3K	Buy	7,924 +482	+6%	+$8.37K	﹤0.01%	137
2025 Q4	$124K	Buy	7,442 +118	+2%	+$2.03K	0.02%	135
2025 Q3	$135K	Hold	7,324	–	–	0.03%	117
2025 Q2	$126K	Buy	+7,324	New	+$129K	0.04%	89

Other funds holding PRTC

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Diadema Partners's PRTC Position: Q1 2026 in Review

Diadema Partners increased its PureTech Health (PRTC) stake by 6.5% in Q1 2026, buying an estimated $8.37K and bringing the position to 7,924 shares worth $11.3K. The position accounts for ﹤0.01% of the portfolio, ranked #137.

Diadema Partners first reported a position in PRTC in Q2 2025 and has held it in 4 quarters since. The position peaked at $135K in Q3 2025. 5 funds tracked by Wall St. Rank hold PRTC as of Q1 2026.

Diadema Partners held 7,924 shares of PureTech Health worth $11.3K as of Q1 2026.
Diadema Partners bought 482 PureTech Health shares in Q1 2026, an estimated $8.37K.
PureTech Health made up ﹤0.01% of Diadema Partners's portfolio in Q1 2026, its #137 holding.
Diadema Partners first reported a position in PureTech Health in Q2 2025 and has held it in 4 quarters since.
Diadema Partners's PureTech Health position peaked at $135K in Q3 2025.
5 funds tracked by Wall St. Rank held PureTech Health as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.